IOVA has climbed more than 400% from its low. Can lung cancer turn Amtagvi into a much bigger franchise?
Iovance approaches new lung cancer data as Amtagvi revenue hits $91 million and IOVA trades near a 52-week high after a major 2026 rally.
Pharma & Biotech
Pharma & Biotech
Replimune survived two FDA rejections and won the panel vote. Why RP1’s hardest question remains unanswered
Replimune Group is awaiting a delayed FDA decision on RP1 after advisers voted that its melanoma results were clinically meaningful. Approval would create a more accessible oncolytic immunotherapy option, but regulators remain divided over whether the single-arm IGNYTE trial reliably proves RP1’s contribution.
Pharma & Biotech
What the Obsidian Therapeutics and Galera Therapeutics merger means for OBX-115
Obsidian Therapeutics closes its Galera merger and $350 million financing, putting OBX-115 melanoma data and execution under investor scrutiny.
Pharma & Biotech
FDA panel supports Replimune’s RP1 melanoma data after two regulatory rejections
A United States Food and Drug Administration (FDA) advisory committee has voted 10 to 3 that efficacy findings from Replimune Group’s IGNYTE study of RP1 plus nivolumab are evaluable and clinically meaningful, handing the experimental melanoma treatment a significant regulatory reprieve after two earlier rejection letters. The committee considered RP1, also known as vusolimogene oderparepvec,